已收盘 01-09 16:00:00 美东时间
-0.190
-1.70%
BofA warns hospitals face profit and volume pressure from policy cuts, favors post-acute care, upgrades Brookdale, and sees select names better positioned to weather challenges.
01-08 04:17
今日重点评级关注:HC Wainwright & Co.:维持MetaVia Inc."买入"评级,目标价从12美元升至40美元;Canaccord Genuity:维持GH Research"买入"评级,目标价从35美元升至39美元
01-07 17:25
B of A Securities analyst Joanna Gajuk upgrades Brookdale Senior Living (NYSE:BKD) from Underperform to Buy and raises the price target from $6.75 to $13.
01-06 21:20
Regency Centers Corporation announced the election of Mark J. Parrell to its Board of Directors, effective January 1, 2026. This increases the Board size to twelve directors. Parrell, currently CEO of Equity Residential, brings extensive real estate experience, including roles as CEO and CFO of a leading S&P 500 company. His leadership is expected to enhance Regency's strategy and shareholder value. Parrell also serves on various industry and com...
2025-12-16 13:15
Brookdale Senior Living Inc: Fourth Quarter-to-Date Occupancy of 82.6% Represen...
2025-12-09 05:45
Brookdale Senior Living (BKD) on Monday said weighted average occupancy of 82.5% for November increased 300 basis points year-over-year and decreased 10 basis points sequentially. Historical sequentia...
2025-12-09 05:25
NASHVILLE, Tenn., Dec. 8, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for November 2025. November 2025 Observations November conso...
2025-12-09 05:15
Brookdale Senior Living Inc. (NYSE:BKD) ("Brookdale" or the "Company") is announcing that Mary Sue Patchett, current Interim Executive Vice President – Community and Field Operations, has been named Chief Operating
2025-11-19 05:16
Tenured Leader Brings 40 Years of Senior Living Experience to Operations BRENTWOOD, Tenn., Nov. 18, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company...
2025-11-19 05:15
今日重点评级关注:HC Wainwright & Co.:维持Oncolytics Biotech"买入"评级,目标价从5美元升至10美元;HC Wainwright & Co.:维持Barinthus Biotherapeutics"买入"评级,目标价从3美元升至4美元
2025-11-18 15:28